In the third court battle between Precision BioSciences and Cellectis, the Triangle firm has won again.

The companies have been fighting in court since 2008.

On Monday, Precision said it prevailed in a lawusit filed in a U.S. federal court.

“This verdict represents a fantastic victory for the Precision BioSciences team and all of our partners,” said Precision BioSciences CEO Matthew Kane. “We will continue to seek to work collaboratively with all members of the biotechnology industry, but we hope this decision underscores that we will defend ourselves vigorously and effectively.”

Precision has won each case either by jury, by a judge, by the U.S. Patent and Trademark Office or a matter was dropped by Cellectis.

The Triangle firm owns more than 15 genome-related patents in the U.S., Europe and Australia. 

The companies remain embroiled in other lawsuits.